Kodiak prices the DAYBREAK option, but the cash clock makes the short a no-trade

Run timestamp: 2026-09-06 05:38 SGT Scope: U.S. market, short only Classification: No-trade screen, Reject for current execution Primary instrument: Kodiak Sciences common stock, Nasdaq, unlevered only if every short-execution gate later passes

Summary: Kodiak Sciences is approaching a September Phase 3 DAYBREAK readout for Zenkuda and KSI-501 in treatment-naive wet AMD. The stock still carries about $2.22 billion of equity value on the latest filed 62.83 million shares, while the June 30 10-Q reports $125.9 million of cash, $86.2 million of six-month operating cash use, and substantial doubt about whether cash covers the next twelve months. The market is paying for a late-stage clinical option, but the company needs the option to arrive before the financing clock becomes the more important denominator.

The short case is real and binary. It is not executable. Kodiak's September 4 regular-session close was $35.36, down 2.75%, with 671,776 shares traded. A StockAnalysis after-hours observation was $35.28 at 19:51 EDT. MarketBeat reports 10.30 million shares short, 29.49% of public float, and 17.5 days to cover as of the August 14 settlement. A positive DAYBREAK result can force a violent repricing before any cash or dilution bridge is visible.

Using $35.36 as a verified regular-session reference, the modeled top, base, and bottom prices are $16.00, $24.00, and $55.00 at probabilities of 30%, 45%, and 25%. The base decline is 32.13%, but the credible adverse rise is 55.54%, producing 0.58:1 gross reward to adverse risk before borrow, spread, slippage, funding, gap, and buy-in costs. The Desk therefore rejects the short under the 10/5 hurdle and keeps entry.price null and execution.can_execute false.

Opportunity Ranking

The search used mechanism-specific queries rather than a generic earnings query:

late-stage ophthalmology topline month cash runway precommercial option dilution days to cover

retailer ticker change inventory normalization earnings high short float debt-free cash

AI investigative software guidance cut free cash flow CEO succession short float

The current-week archive and September signal file were scanned before selection. Existing current-week names and mechanisms, including IONS's failed pelacarsen endpoint, WFRD's redomestication cash bridge, USAR's resale shelf, SUNB's rental-cycle reset, and the earlier software and retail expectation notes, were excluded. KOD is not a prior article or signal in the archive. SHOE and CLBT are comparison candidates with different current evidence boundaries.

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Kodiak Sciences (KOD)	Short	The market capitalizes a September registrational option while cash coverage and potential financing need remain unresolved	Aug. 13 primary result, June 30 10-Q, Sep. 4 tape, Sep. 4 indicative borrow	DAYBREAK one-year primary endpoint, expected in September 2026	29.49% of public float short and 17.5 DTC as of Aug. 14; borrow fee is indicative only	Reject	Nasdaq-listed with ordinary daily volume, but binary data, thin depth, and high short crowding can produce a gap	Positive DAYBREAK data can create a multi-day squeeze before financing risk is repriced
2	Shoe Station Group (SHOE, formerly SCVL)	Short	Weak sales and margin pressure meet a September 10 earnings catalyst, but the company has cash, no debt, and an inventory-reduction plan	May 21 primary result, Sep. 4 tape, Sep. 10 earnings schedule	Q2 fiscal 2026 results on September 10	36.80% of public float short and 13.7 DTC as of Aug. 14	Reject	Roughly 1.02M shares traded on Sep. 4, but the ticker transition and crowded positioning complicate execution	Debt-free balance sheet, $129.3M cash, and lower inventory can support a beat
3	Cellebrite DI (CLBT)	Short	ARR and revenue guidance were cut after longer sales cycles, but free cash flow and 21% ARR growth remain strong	Aug. 13 primary result, Sep. 4 tape, and Q2 materials	Sep. 14 investor event and next operating update	3.26% of public float short and 1.4 DTC as of Aug. 14	Reject	Nasdaq-listed and liquid enough for research, but the current selloff is already large	$144.2M trailing free cash flow, 80.8% GAAP gross margin, and new-product adoption

Selected research subject: KOD.

Why this one now: It combines a near-term clinical readout, a filed going-concern warning, a measurable cash clock, and the most extreme short crowding in the fresh screen. The same factors that create downside also create a measurable squeeze path, so the correct output is a well-defined no-trade screen.

What should surprise the reader: A 29.49% short float is not evidence that the market has already agreed with the bear case. In KOD it is part of the payoff problem. If DAYBREAK clears non-inferiority and the durability narrative survives, short covering can dominate the cash story for long enough to make a correct long-term financing thesis a bad short-term trade.

No-trade conclusion: KOD is the best current short research subject by catalyst urgency and evidence tension, not the best executable opportunity. The high short float, binary readout, missing live locate, and very wide adverse path force Reject.

Why This Is the Best Opportunity Right Now

The strongest counterparty case is substantial. Kodiak's official pipeline lists four successful Phase 3 studies for Zenkuda across diabetic retinopathy and retinal vein occlusion, including GLOW1, GLOW2, BEACON, and DAYLIGHT. The company says DAYBREAK is a registrational study for both Zenkuda and KSI-501, with topline data expected in the third quarter of 2026. The August 13 release says the study is designed to evaluate Zenkuda and KSI-501 against aflibercept, and that the primary endpoint is non-inferiority in visual acuity over Weeks 40, 44, and 48. Kodiak pipeline, Kodiak Q2 2026 release

That is a credible route to approval value. The market is not irrational for assigning option value to a late-stage asset with prior positive Phase 3 evidence. The disagreement is about the price of time. Kodiak's June 30 10-Q reports $125.9 million of cash and a six-month operating cash use of $86.2 million. At the same simple burn rate, unrestricted cash covers about 8.76 months of operating use before capital spending, working-capital changes, restricted cash, financing costs, or readout-related changes. The same filing says existing cash may not be sufficient for anticipated operating and capital requirements during the following twelve months and discloses substantial doubt about going concern. Kodiak June 30, 2026 Form 10-Q

The issuer's August 13 release says current cash and cash equivalents are expected to support current and planned operations into 2027. That is a company statement, not an independent runway proof. The conflict between that forward-looking claim and the 10-Q risk language is the core cash bridge. It does not prove a near-term equity raise. It does prove that the market must eventually reconcile the readout with financing capacity.

SHOE has a nearer earnings date, but its Q1 release showed $129.3 million of cash and marketable securities, no debt, improving sales declines, and an inventory-reduction plan. CLBT's guide reset is real, but the same primary release reports 21% ARR growth and $144.2 million of trailing free cash flow. KOD has the cleanest binary downside and the least balance-sheet time, so it wins the information ranking while failing the short risk hurdle.

Why This Can Move More Than 5% Soon

The stock has already moved from $46.87 on August 7 to $35.36 on September 4, a 24.5% decline. The remaining move can still exceed 5% because three connected states are unresolved:

DAYBREAK will test a one-year primary endpoint in a treatment-naive wet AMD population. It evaluates both Zenkuda and KSI-501 against aflibercept, so one release can change the value of two programs.
The company is precommercial and has no product revenue. A failed or ambiguous result increases the probability that the next capital raise arrives before commercial cash.
A positive result can force a large number of shares to cover. MarketBeat's 17.5 DTC is calculated from a pre-readout settlement, not from current borrow availability, but it shows how much potential buying sits in the positioning structure.

The event is close enough that there is no need to invent a distant valuation catalyst. The question is whether the expected value of the readout is already reflected in a $2.22 billion equity value against a $125.9 million cash balance and a $86.2 million first-half operating cash burn.

10/5 Asymmetry Gate

The hurdle is measured from the completed regular-session close. The after-hours observation is recorded separately and is not used as an entry.

Measure	Reference-only result	Interpretation
Reference price	$35.36	StockAnalysis regular-session close at 2026-09-04 16:00 EDT
Latest after-hours context	$35.28	StockAnalysis observation at 2026-09-04 19:51 EDT; not an executable entry
Top-case target	$16.00	54.75% favorable underlying decline
Base-case target	$24.00	32.13% favorable underlying decline
Bottom-case target	$55.00	55.54% adverse underlying rise
Gross reward to adverse risk	0.58:1	($35.36 - $24.00) / ($55.00 - $35.36), below the required 2:1
Probability-weighted target	$29.35	30% top, 45% base, 25% bottom; price-only estimate
Price-only expected decline	17.00%	($35.36 - $29.35) / $35.36 before costs
Measurement basis	Reference-only	`entry.price` is null
Status	Reject / no-trade screen	Credible adverse path and execution gaps are decisive

The base case clears the favorable 10% threshold and the price-only expected decline is positive. Neither proves a trade. The adverse move is more than eleven times the permitted 5% boundary, while the gross reward-to-adverse-risk ratio is below 2:1 before borrow, spread, slippage, funding, recall, buy-in, and gap costs. The scenario probabilities are subjective model estimates, not observed clinical frequencies.

What Should Surprise the Reader

KOD is not a revenue-multiple short. It is a precommercial option whose cash clock matters only if DAYBREAK fails, disappoints on durability, or takes too long to convert into financing or approval.
The company has prior positive Phase 3 evidence. That makes a positive DAYBREAK result plausible and makes the high short interest dangerous. Prior success is not proof of DAYBREAK success, but it is a stronger counterparty fact than a generic biotech narrative.
The cash clock is shorter than the company's optimistic “into 2027” wording when measured against the six-month operating burn. That comparison is a diagnostic, not a precise liquidation date.
The denominator is not just the 62.83 million issued shares. The June 30 10-Q lists 21.69 million outstanding stock options, unvested restricted shares, and ESPP shares in its diluted-share table. These are conditional claims, not current float, and should not be added mechanically without strike and vesting terms.
The likely near-term path is not simply “bad data, lower price.” A failed readout can coincide with a financing announcement, while a good readout can trigger a squeeze before dilution is disclosed.

The Setup

Kodiak's August 13 primary release says DAYBREAK topline data for the one-year primary endpoint are expected in September 2026. The study evaluates Zenkuda and KSI-501 in treatment-naive wet AMD, with aflibercept as the active comparator. The release describes the study as non-inferiority for visual acuity, with the primary endpoint based on average change from baseline over Weeks 40, 44, and 48. KSI-501 also has a separate Phase 3 ALTO study in diabetic macular edema, but ALTO is enrolling and does not provide a current commercial result.

The same release gives the bull case: prior GLOW1, GLOW2, BEACON, and DAYLIGHT results support Zenkuda's durability and the company's planned BLA path. The company describes KSI-501 as a bispecific anti-IL-6 and VEGF therapy intended to extend durability and add efficacy beyond VEGF. Those are issuer descriptions and research goals, not approval or revenue.

The filed financial state is less forgiving. The June 30 balance sheet reports $125.903 million cash, $6.184 million restricted cash, $100.0 million of liability related to the sale of future royalties, $52.756 million of operating lease liabilities, and $61.096 million of stockholders' equity. The six-month income statement reports $126.615 million of operating expenses, a $126.615 million operating loss, and a $123.801 million net loss. The cash-flow statement reports $86.247 million of operating cash use.

The royalty liability is not a simple debt maturity. It represents a $100 million liability related to a sale of future royalties and should be reconciled to the royalty asset, payments, and future obligations. It does, however, sit ahead of common equity in the claim ledger. The company also owns facilities and leases, and its 10-Q warns that additional capital may be required. A cash-per-share calculation without these claims would overstate protection.

At the $35.36 close and 62.830860 million issued shares, the simple equity arithmetic is about $2.222 billion. Cash and cash equivalents alone are about $2.00 per issued share. That cash is valuable, but it is not a floor. It is the budget for the trial, manufacturing, regulatory, and corporate bridge that must carry the company to a commercial or financing state.

The Market Price

Field	Observation	Timestamp or date	Source and limitation
Regular-session close	$35.36	2026-09-04 16:00 EDT	StockAnalysis KOD history; completed market print
Regular-session change	-$1.00, -2.75%	Same session	Same source
Regular-session range and volume	$35.18 to $36.62; 671,776 shares	Same session	Same source; volume does not prove exit capacity
Extended-hours observation	$35.28, -0.23% from close	2026-09-04 19:51 EDT	StockAnalysis KOD history; non-executable reference context
Shares outstanding	62,830,860	2026-06-30	Kodiak Q2 Form 10-Q; later changes unknown
Implied equity value at close	About $2.222B	$35.36 multiplied by 62.830860M shares	Derived reference arithmetic, not a valuation floor
Simple unrestricted cash runway	About 8.76 months	$125.903M divided by six-month operating cash use annualized	Derived from the 10-Q; not a forecast and excludes financing, trial timing, capex, and working capital

The latest regular-session print is the correct starting point for a weekend research run. The after-hours quote is shown because the stock is a binary readout name, but it cannot authorize an entry. Current bid, ask, spread, depth, venue quality, volume quality, and realistic exit liquidity are not verified.

I do not have sufficient reliable data to quantify this accurately for a live locate, borrow, or executable exit.

The Mispricing

Fact: The company expects September 2026 topline data for the one-year primary endpoint in DAYBREAK, a registrational study for Zenkuda and KSI-501 in treatment-naive wet AMD. Kodiak Q2 2026 release

Fact: The June 30 10-Q reports $125.9 million cash, $86.2 million six-month operating cash use, $126.6 million six-month operating expenses, and substantial doubt about whether cash is sufficient for the following twelve months. Kodiak June 30, 2026 Form 10-Q

Fact: The stock closed at $35.36 on September 4 with 671,776 shares traded, and the same page showed a $35.28 after-hours observation. StockAnalysis KOD history

Fact: MarketBeat reports 10.30 million shares short, 29.49% of public float, and 17.5 days to cover as of August 14. MarketBeat KOD short interest

Inference: The price can still contain a meaningful probability of a successful or commercially differentiated DAYBREAK result, because the company has prior positive Phase 3 evidence and a registrational design. At the same time, the equity value gives the clinical option time that the filed cash state may not independently provide.

Reasonable assumption: If the primary endpoint is missed or met without a meaningful durability advantage, Kodiak may need to finance before its programs generate operating cash. A discounted cash and pipeline state could move the equity toward the $24 base case or the $16 top case.

Unknown: The DAYBREAK event date, the statistical result, durability data, any subgroup signal, the next financing instrument, its price and dilution, live borrow and recall terms, and the post-event cash balance.

The mispricing is therefore not “KOD is going to zero.” The short disagreement is that a precommercial company with a roughly $2.22 billion equity value may be priced for a favorable registrational option while the 10-Q's cash and going-concern language requires a second financing or a sufficiently strong readout. The bull case is that prior Phase 3 success makes the option worth much more than the current cash burn implies.

The Positioning

MarketBeat's August 14 data show 10,303,453 shares short, 29.49% of public float, and 17.49 days to cover. Short interest increased 0.72% from the prior report. These are FINRA-derived settlement observations published before the September readout window; they are not current post-event positions. MarketBeat KOD short interest

CurvedTrading displayed an indicative 0.3% borrow fee as of 2026-09-04T08:20Z and described 10.3 million shares short. That public loan snapshot is useful market context but not an account-level locate, a recall guarantee, a utilization measure, or cover capacity in a binary move. CurvedTrading KOD borrow context

Positioning is the reason KOD ranks ahead of a cleaner fundamental short. The short float can accelerate a post-readout decline if the result fails. It can also create a reflexive rise if the result is positive, the release is delayed, or the stock opens through the available offer. Current options open interest, dealer gamma, holder concentration, fund flows, and live borrow allocation are not verified.

Current positioning score: 5/5 for tension, 2/5 for completeness. The reported float and DTC are extreme, but the inputs are stale and the actual execution state is missing. A crowded short is evidence of disagreement, not a guarantee of downside.

The Catalyst

Step	State	Timing	Observable test	Failure mode
DAYBREAK topline	Announced and pending	September 2026; exact date not stated by the company	Read the primary endpoint, effect estimates, confidence intervals, safety, and durability for both arms	Non-inferiority failure, weak durability, or an ambiguous result removes the clean approval path
Zenkuda regulatory path	Preparation in progress	After DAYBREAK; date not verified	Verify BLA submission timing, contents, and any regulatory feedback	A strong clinical result does not guarantee filing or approval
KSI-501 follow-on	ALTO enrolling	Ongoing; no result date verified	Verify enrollment, design, comparator, and funding after DAYBREAK	A failed DAYBREAK result leaves the second program earlier and more expensive
Financing and denominator	Unknown	Before or after readout, if needed	Reconcile cash, burn, instrument, price, warrants, options, and post-financing shares	A raise can fund operations but transfer value from existing common holders
Short response	Unknown	First regular session after the readout	Verify opening price, close, volume, spread, depth, borrow, recall, settlement, and cover liquidity	A squeeze, halt, or thin reopening makes modeled levels unusable

The cheapest falsification sequence is: first read the complete DAYBREAK dataset, then check whether Kodiak has announced a financing or a cash-preservation action, then reconcile the first post-readout cash and denominator filing. A robust endpoint with a viable regulatory path and no immediate financing need invalidates the short. A failed endpoint with a priced financing or persistent burn strengthens the thesis, but still does not clear the execution gate.

The Payoff

The one stated holding window runs from the next regular session after the readout through the first post-readout financing or cash-flow disclosure. The company has not given a specific readout date, so the horizon is event-defined rather than a calendar promise.

The top case is $16.00 if DAYBREAK fails in both arms or produces no usable durability advantage, financing becomes urgent, and the market removes most late-stage option value. The base case is $24.00 if the result is negative or ambiguous, KOD preserves the program at lower value, and a financing or expense reset absorbs part of the remaining cash. The bottom case is $55.00 if both programs produce a strong result, the BLA path is credible, and short covering outruns the next denominator update.

Probability rationale: The 30% top case reflects the cash warning and the historical base rate that development programs do not all reach approval. The 45% base case is highest because a mixed or partial result is more plausible than a clean binary extreme when two products and a durability objective are reported together. The 25% bottom case reflects the company's four prior positive Phase 3 studies and the 29.49% short float. These are subjective estimates, not observed frequencies.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	30%	$16.00	54.75% favorable short move from $35.36	Event-defined through first financing or cash-flow disclosure	DAYBREAK fails or lacks durable differentiation, cash pressure rises, and financing risk is repriced	Medium
Base Case	45%	$24.00	32.13% favorable short move from $35.36	Same	Result is negative or ambiguous, option value falls, and cash buys time but not a commercial bridge	Medium
Bottom Case	25%	$55.00	55.54% adverse rise from $35.36	Same	DAYBREAK is strong, BLA path is credible, and 29.49% short float covers into limited supply	Medium
Invalidation	n/a	Strong DAYBREAK efficacy and durability plus a funded regulatory path without urgent dilution	n/a	Same	Remaining option value is demonstrated and financing pressure is reduced	High / Medium

Probability-weighted expected value: 0.30 x $16.00 + 0.45 x $24.00 + 0.25 x $55.00 = $29.35, a 17.00% price-only expected decline before costs.

Primary instrument: KOD common stock, unlevered only after every short-execution gate passes.

10/5 favorable base move: 32.13% underlying decline from the regular-session reference.

10/5 credible adverse move: 55.54% underlying rise from the regular-session reference.

10/5 measurement basis: Reference-only, not verified executable entry.

10/5 status: Reject.

Confidence: Medium on the filed cash and clinical-event facts; low to medium on scenario targets because the readout date, result, financing state, and live borrow are unresolved.

The Kill Shot

The mature counterparty says KOD is misclassified as a cash-burn biotech. The company has four successful Phase 3 studies for Zenkuda, a registrational DAYBREAK study for two programs, and a commercial opportunity in wet AMD where dosing durability can matter. Positive results can support a BLA and a strategic partnership, making the $2.22 billion equity value modest relative to potential future revenue. The company says cash supports planned operations into 2027.

That argument defeats a simplistic liquidation short. It does not remove the financing and timing problem. Kodiak is precommercial, reported $86.2 million of first-half operating cash use, and disclosed substantial doubt about cash sufficiency for the next twelve months. The load-bearing assumption for the short is that DAYBREAK will not convert into enough approval value quickly enough to avoid dilution or a lower-quality financing path.

The short can lose even if that assumption is eventually right. A successful readout can lift the stock first. A financing can be priced above the short's entry and remove near-term runway risk. A broker can recall shares. A halt or a thin reopening can make a modeled bottom case far too small. The 10/5 rejection is not a judgment that the company will succeed. It is a judgment that the payoff path is unsafe to express in common stock before the event.

What Could Go Wrong

Clinical success risk: Prior GLOW1, GLOW2, BEACON, and DAYLIGHT Phase 3 results are evidence that the platform can produce positive clinical outcomes. They are not proof of DAYBREAK, but they make the bottom case credible.

Durability risk: The market may reward a non-inferiority result even if a six-month dosing interval is not fully established. A short thesis based on a missed durability story can fail if the primary endpoint is enough for approval.

Financing risk: A funded partnership, equity raise, royalty transaction, or cost reduction can extend runway. Financing can be positive for survival and negative for common per-share value at the same time.

Cash-floor risk: $125.9 million cash and $6.2 million restricted cash are meaningful assets. They are not distributable cash because Kodiak has clinical, manufacturing, lease, and corporate obligations.

Crowded-short risk: 29.49% of public float and 17.5 DTC are pre-event figures. A positive result or favorable financing can create forced buying well beyond a 5% adverse move.

Gap and halt risk: A clinical result can cause an opening gap, trading halt, or delayed reopening. A stop order cannot guarantee a 5% exit.

Liquidity risk: The latest regular session traded 671,776 shares, but current spread, depth, venue quality, volume quality, and realistic cover liquidity are unverified.

Borrow risk: The indicative 0.3% public fee does not establish an account-level locate, recall duration, utilization, buy-in terms, or settlement certainty.

Denominator risk: The 10-Q lists 21.69 million stock options and related conditional claims. A financing or exercise can change the common denominator even if the clinical thesis is unchanged.

What Would Prove This Wrong

The short thesis is invalidated by a demonstrated change in the cash and option bridge:

DAYBREAK meets its primary endpoint for the relevant arms and reports clinically useful durability or efficacy evidence.
Kodiak provides a credible BLA path, regulatory interaction, and manufacturing plan without an urgent dilutive financing.
A partner funds or purchases rights on terms that materially reduce common-equity financing risk.
The next filing shows operating cash use falling materially, cash extending beyond the 10-Q warning, and no adverse denominator event.
After the readout, a regular-session market audit verifies stable price acceptance, borrow continuity, acceptable spread and depth, and an adverse path within 5%.

The fifth condition is separate from thesis invalidation. A good business outcome does not automatically make a short executable.

Risk Audit

Risk	Evidence	Control
Clinical binary	DAYBREAK is a registrational Phase 3 readout expected in September	No common-stock short before the result is read and the opening market is independently audited
Cash and going concern	$125.9M cash, $86.2M six-month operating cash use, and 10-Q substantial-doubt language	Reconcile post-event cash, burn, financing, royalty liability, lease obligations, and denominator
Short squeeze	29.49% of float and 17.5 DTC at Aug. 14	Model $55 bottom; reject the expression while adverse rise remains above 5%
Borrow and recall	Indicative 0.3% fee only; account-level terms missing	Require broker locate, fee, utilization, recall, buy-in, and settlement evidence
Gap and halt	Clinical releases can gap or halt	Do not treat a stop order or after-hours print as protection
Liquidity and exit	671,776 regular-session shares do not prove depth or cover capacity	Verify bid, ask, spread, depth, venue, volume quality, and realistic exit liquidity
Denominator	62.83M shares outstanding and 21.69M conditional claims	Separate issued shares, options, restricted shares, financing shares, and actual settlement
Instrument	No live option chain or maximum-loss audit was verified	Common stock only in research state; no options, leverage, margin, market orders, or price floors

Best Trade Strategy

Current decision: No executable trade. KOD is a Reject under the short 10/5 policy and remains a research-only screen.

Primary expression: Unlevered KOD common stock only after the DAYBREAK result is fully reviewed and a fresh regular-session quote, broker-level locate, current borrow fee, utilization, recall and buy-in terms, acceptable bid and ask, spread, depth, venue quality, volume quality, settlement, and realistic exit liquidity are verified. These are research conditions, not an order.

Reference-only levels: Top $16.00, base $24.00, bottom $55.00. The invalidation state is a strong, funded clinical and regulatory path with improving cash coverage, not a mechanical stop.

Horizon: From the first regular session after DAYBREAK through the first financing or cash-flow disclosure. The exact readout date is not verified.

Do not trade when: the only price is pre-market or extended hours; the readout is pending; the full dataset is unavailable; the stock opens above the $55 stress level; locate, borrow, recall, buy-in, spread, depth, venue, volume quality, settlement, or exit liquidity is unknown; or a financing or partner transaction changes the denominator without a new bridge.

Alternative: A defined-loss put or put spread might limit squeeze exposure, but no live option chain, spread, implied volatility, expiry, assignment terms, or maximum-loss analysis was verified. It is not an approved substitute.

Sources

Kodiak Sciences Q2 2026 results - DAYBREAK design, September 2026 readout, KSI-501, cash position, net loss, and operating context, August 13, 2026.
Kodiak Sciences June 30, 2026 Form 10-Q - cash, restricted cash, royalty liability, leases, shares, options, operating expenses, cash use, and going-concern disclosure, filed August 13, 2026.
Kodiak Sciences pipeline - Phase 3 history, DAYBREAK registrational design, and stated timing, accessed September 6, 2026.
Kodiak regular-session and extended-hours price history - September 4 close, range, volume, and after-hours observation.
Kodiak short interest - 10.30M shares short, 29.49% public float, 17.5 DTC, and settlement history through August 14, 2026.
Kodiak indicative borrow context - public borrow fee snapshot and limitations, September 4, 2026.
Shoe Station Group Q1 2026 results - comparison candidate: sales, margin, cash, debt-free balance sheet, inventory, and fiscal guidance, May 21, 2026.
Shoe Station Group price history - comparison candidate: current ticker, September 4 close, range, volume, and name-change context.
Shoe Station Group short interest - comparison candidate: 36.80% public float and 13.7 DTC as of August 14, 2026.
Shoe Station Group earnings schedule - comparison candidate: September 10, 2026 Q2 results schedule.
Cellebrite Q2 2026 results - comparison candidate: CEO succession, ARR and revenue growth, guidance cut, margins, free cash flow, and product adoption, August 13, 2026.
Cellebrite price history - comparison candidate: September 4 close and volume.
Cellebrite short interest - comparison candidate: public short interest and DTC as of August 14, 2026.

Research Quality Scorecard

Criterion	Score	Evidence and deduction
Market disagreement	5/5	A near-term registrational option meets a filed cash and going-concern warning, with a clear financing and denominator tension
Evidence base	5/5	Fresh company release, SEC 10-Q, primary pipeline page, regular-session tape, and FINRA-derived short data
Positioning and flows	3/5	Short float and DTC are extreme, but stale; live locate, utilization, recall, holder, dealer, and post-event flow data are missing
Catalyst path	4/5	DAYBREAK, regulatory, financing, and cash-flow steps are observable; exact readout date is not published
Payoff architecture	3/5	Targets and probabilities are explicit, but the adverse squeeze defeats the 10/5 hurdle
Invalidation discipline	4/5	Clinical, regulatory, financing, cash, denominator, and execution invalidators are monitorable
Differentiated insight	4/5	The key disagreement is clinical option value versus cash time and financing state, not a generic biotech short
Client value	5/5	The screen shows why the strongest short research subject is still unsafe to chase before a binary readout

Total: 33/40. The score supports a substantive no-trade screen. It does not override the 55.54% credible adverse move, the failed 10/5 ratio, or missing execution gates.

Bottom Line

Kodiak's DAYBREAK readout is the most important near-term fact in this U.S.-listed short screen. The bear case has a hard financial bridge: $125.9 million of cash, $86.2 million of first-half operating cash use, a precommercial model, and a filed warning that cash may not cover the next twelve months. The bull case is equally concrete: four prior positive Phase 3 studies and a registrational design that can create substantial option value.

KOD is therefore the best current short research subject but not a qualified trade. The reference price is a completed regular-session close, not a fill. The reported short float is fuel and a squeeze liability. The target map offers positive price-only expected value but fails on adverse risk and gross ratio. The Desk's decision is Reject and wait for primary data, financing state, borrow, and regular-session execution evidence.

AI Illustration Prompt

Create a restrained editorial illustration for The Mispricing Desk: a retinal clinical-trial dossier marked “DAYBREAK” rests on a transparent glass balance sheet beside a nearly empty cash runway gauge, a small calendar page marked “September 2026,” and two sealed vials labeled “Zenkuda” and “KSI-501.” In the background, a dense crowd of black paper figures presses toward a narrow exit door to represent 29.49% short float and 17.5 days to cover, while a thin red line rises sharply through the doorway as the squeeze path. Use graphite, bone paper, muted cobalt, pale clinical green, and one controlled warning-red accent; precise financial-document textures, sober medical-science atmosphere, no logos, no generic candlestick chart, no dollar-bill imagery, no trading instructions. Leave generous negative space for a headline and include a subtle readable “The Mispricing Desk” watermark in the lower-right corner.